ArticleMolecular and cellular biology1994
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
Article in Molecular and cellular biology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 58 citations in OpenAlex.
- Invoking the power of thrombospondins: regulation of thrombospondins expression.Matrix biology : journal of the International Society for Matrix Biology · 2014Review
- Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.Angiology: open access · 2013Article
- Carcinogenic effect of nickel compounds.Molecular and cellular biochemistry · 2005Review
- Inhibition of core histones acetylation by carcinogenic nickel(II).Molecular and cellular biochemistry · 2005Article
- Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression.Molecular and cellular biochemistry · 2005Article
- Ascorbate depletion: a critical step in nickel carcinogenesis?Environmental health perspectives · 2005Review
- Molecular mechanisms in nickel carcinogenesis: modeling Ni(II) binding site in histone H4.Environmental health perspectives · 2002Review
- p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.Oncogene · 2001Article
- In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.Genes & development · 2001Article
- Nickel carcinogenesis, mutation, epigenetics, or selection.Environmental health perspectives · 1999Article
- Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.The American journal of pathology · 1999Article
- Article
- The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun.Oncogene · 1999Article
- Peroxidase deficiency of nickel-transformed hamster cells correlates with their increased resistance to cytotoxicity of peroxides.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 1996Article
- Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens.Molecular and cellular biology · 1995Article
- SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts.The EMBO journal · 1994Article
- Molecular mechanisms of nickel carcinogenesis.Environmental health perspectives · 1994Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
mRNA from normal Chinese hamster embryo (CHE) cells was transcribed to cDNA and subtracted with an excess of mRNA from Chinese hamster embryo cells transformed by nickel compounds. Here we report the recovery of a sequence found to be highly homologous to the mouse thrombospondin 1 gene that was obtained by this subtraction procedure. Since thrombospondin is antiangiogenic, cancer cells expressing high levels of thrombospondin cannot grow in vivo because capillaries will not proliferate to cells secreting thrombospondin. To examine expression of thrombospondin, normal CHE cells were stained with monoclonal antibodies to human thrombospondin. The protein was present abundantly in the cytoplasm of normal cells but at greatly reduced levels in Ni-transformed cells. Analysis of mRNA by Northern (RNA) blot revealed transcripts in normal cells but little thrombospondin mRNA in Ni-transformed cells. Loss of thrombospondin mRNA expression was related to Ni treatment rather than transformation, since Ni-resistant cells also exhibited fewer thrombospondin transcripts than did wild-type cells. Digestion of genomic DNA with various combinations of restriction enzymes revealed thrombospondin gene patterns that were identical in both cell types, suggesting that there were no major deletions or rearrangements of the gene in the nickel-transformed cells. The inactivation of the thrombospondin gene was further investigated by analyzing the promoter activity of this gene linked to a chloramphenicol acetyltransferase (CAT) reporter plasmid that was transfected into normal and Ni-transformed cells. The CAT activity in normal cells was significantly higher than in Ni-transformed cells, suggesting that the promoter region of thrombospondin was less efficiently transcribed in Ni-transformed cells. We studied the consequences of enhanced expression of the retinoblastoma (Rb) gene, a known tumor suppressor gene, on CAT transcription driven by the human thrombospondin promoter. Cotransfection of an expression vector containing the mouse Rb gene greatly enhanced the transcription from the thrombospondin promoter such that the expression was higher in normal cells than in transformed cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.